No profile data available.
Maze Therapeutics, Inc. (MAZE) is a healthcare company in the metabolic process treatment drugs industry, based in South San Francisco, United States, with about 141 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$131.12 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.51 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Maze Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $167.50 million in fiscal year 2024. In Q2 2026 revenue was $0.
$1.51 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include BioMarin Pharmaceutical Inc. (BMRN), NewAmsterdam Pharma Company N.v. (NAMS), Disc Medicine, Inc. (IRON), Zevra Therapeutics, Inc. (ZVRA).